![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug
Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug
The FDA granted breakthrough therapy designation to Boehringer Ingelheim’s Spevigo (spesolimab) as a treatment to prevent flares in adults with generalized pustular psoriasis (GPP).
GPP is a rare and systemic skin disease characterized by flares of painful, sterile pustules eruptions across the body, and can potentially be life-threatening.
The designation was granted based on the results of a Phase 2 clinical trial demonstrating that spesolimab can prevent flares in adolescents and adults with GPP up to 48 weeks.
The breakthrough therapy designation speeds the development and review of a medicine that may offer substantial improvement compared to the available standard of care for the treatment of a serious or life-threatening disease.
Related Topics
Upcoming Events
-
21Oct